文献速递肾小球疾病慢性肾脏病

持续性临床缓解对狼疮性肾炎患者狼疮复发及肾功能受损风险的影响

Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2024-01-19

该回顾性研究纳入303例经活检证实的狼疮性肾炎患者,中位随访14.8年,评估持续性临床缓解(sCR)的概率及其对疾病复发和肾功能受损(IKF)的影响。84.8%患者达到sCR,15年时达90%;sCR持续时间越长,复发风险越低(<5年、5-10年、>10年分别为10%、5%、2%),且sCR及其持续时间对IKF有保护作用。

要点

  • sCR在狼疮性肾炎中可达,15年累积概率达90%。
  • sCR持续越长,狼疮复发风险越低。
  • sCR及其持续时间可降低肾功能受损风险。

核心结论

  • sCR是狼疮性肾炎管理中可实现的目标,并能预防肾功能受损。
  • sCR持续时间越长,其持续概率越高且SLE复发风险越低。

研究设计与样本

  • 回顾性研究,纳入303例经活检证实的狼疮性肾炎患者,中位随访14.8年(IQR 9.8-22)。

主要发现

  • 257例(84.8%)达到sCR,15年时达到sCR的概率为90%。
  • 达到sCR的患者中142例(55.3%)在中位3.6年(IQR 2.3-5.9)后出现狼疮复发,其余115例sCR持续9.5年(IQR 5.8-14.5)。
  • sCR持续15年的概率为38%。
  • sCR持续<5年、5-10年、>10年的患者SLE复发风险分别降至10%、5%、2%。
  • 末次观察时57例(18.81%)存在IKF;sCR达成(HR 0.18,P<0.001)及其持续时间(HR 0.83,P<0.001)对IKF有保护作用。

关键数值与推荐

  • sCR定义:临床SLEDAI-2K=0且eGFR>60 ml/min per 1.73 m²持续≥1年。
  • IKF定义:eGFR<60 ml/min per 1.73 m²持续>3个月。
  • 基线年龄(HR 1.017;95%CI 0.005-1.029;P=0.004)、羟氯喹使用(HR 1.385;95%CI 1.051-1.825;P=0.021)及无动脉性高血压(HR 0.699;95%CI 0.532-0.921;P=0.011)是sCR的独立预测因素。

临床怎么用

  • 应将sCR作为狼疮性肾炎的治疗目标,并努力维持长期缓解以降低复发和肾功能受损风险。
  • 对达到sCR的患者需持续监测,因即使sCR后复发仍常见,且sCR持续概率随时间下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This retrospective study on patients with biopsy-proven lupus nephritis (LN) aimed to assess the probability of sustained clinical remission (sCR) and to investigate sCR effects on disease flares and impaired kidney function (IKF). METHODS: sCR was defined as clinical-Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) = 0 and estimated glomerular filtration rate (eGFR) >60 ml/min per 1.73 m2 lasting ≥1 year; IKF: eGFR <60 ml/min per 1.73 m2 for >3 months. We analyzed the probability of achieving and maintaining sCR, and the yearly risk of flare. Cox models were used to identify predictors of sCR and IKF with variables analyzed as time-dependent covariates when appropriate. RESULTS: Of 303 patients followed-up with for 14.8 (interquartile range: 9.8-22) years, 257 (84.8%) achieved sCR. The probability of achieving sCR progressively increased over time reaching 90% at 15 years. Baseline age (hazard ratio [HR]: 1.017; 95% confidence interval [CI]: 0.005-1.029; P = 0.004), hydroxychloroquine intake (HR: 1.385; 95% CI: 1.051-1.825; P = 0.021), and absence of arterial hypertension (HR: 0.699; 95% CI: 0.532-0.921; P = 0.011) were independent predictors of sCR. Among patients who achieved sCR, 142 (55.3%) developed a lupus flare after a median time of 3.6 (2.3-5.9) years. In the remaining 115 patients, sCR persisted for 9.5 (5.8-14.5) years. The probability of sCR to persist at 15 years was 38%. SLE flare risk decreased to 10%, 5%, and 2% in patients with sCR lasting <5, 5 to 10, and >10 years, respectively. At the last observation, 57 patients (18.81%) had IKF. sCR achievement (HR: 0.18, P < 0.001) and its duration (HR: 0.83, P < 0.001) were protective against IKF. CONCLUSION: sCR is an achievable target in LN management and protects against IKF. The longer the sCR, the higher the chance of its persistence and the lower the risk of SLE flares.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gatto M, Frontini G, Calatroni M, et al. Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis. Kidney Int Rep. 2024. PMID: 38765576. doi:10.1016/j.ekir.2024.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。